Evidence map›Paper›PMID 42307715›Full record

Observational studyLung2026

Clinically Meaningful Differences for Cough-Specific Visual Analogue Scale in Chronic Cough: A Real-World Study.

Mami Rikimaru, Junpei Saito, Surinder S Birring, Atsuro Fukuhara, Yasuhito Suzuki, Ryuki Yamada, Tetsuya Egawa, Takahiro Kumanaka, Ryutaro Tanaka, Kentaro Kazama and 14 more

Abstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in Lung, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Mami RikimaruDepartment of Pulmonary Medicine, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima City, Fukushima Prefecture, 960-1295, Japan.
Junpei SaitoDepartment of Pulmonary Medicine, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima City, Fukushima Prefecture, 960-1295, Japan. junpei@fmu.ac.jp.
Surinder S BirringCentre for Human and Applied Physiological Sciences, School of Basic and Medical Biosciences, King's College London, London, UK.
Atsuro FukuharaDepartment of Pulmonary Medicine, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima City, Fukushima Prefecture, 960-1295, Japan.
Yasuhito SuzukiDepartment of Pulmonary Medicine, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima City, Fukushima Prefecture, 960-1295, Japan.
Ryuki YamadaDepartment of Pulmonary Medicine, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima City, Fukushima Prefecture, 960-1295, Japan.
Tetsuya EgawaDepartment of Pulmonary Medicine, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima City, Fukushima Prefecture, 960-1295, Japan.
Takahiro KumanakaDepartment of Pulmonary Medicine, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima City, Fukushima Prefecture, 960-1295, Japan.
Ryutaro TanakaDepartment of Pulmonary Medicine, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima City, Fukushima Prefecture, 960-1295, Japan.
Kentaro KazamaDepartment of Pulmonary Medicine, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima City, Fukushima Prefecture, 960-1295, Japan.
Koshi SaitoDepartment of Pulmonary Medicine, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima City, Fukushima Prefecture, 960-1295, Japan.
Rina HariganeDepartment of Pulmonary Medicine, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima City, Fukushima Prefecture, 960-1295, Japan.
Riko SatoDepartment of Pulmonary Medicine, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima City, Fukushima Prefecture, 960-1295, Japan.
Hikaru TomitaDepartment of Pulmonary Medicine, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima City, Fukushima Prefecture, 960-1295, Japan.
Natsumi WatanabeDepartment of Pulmonary Medicine, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima City, Fukushima Prefecture, 960-1295, Japan.
Takashi UmedaDepartment of Pulmonary Medicine, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima City, Fukushima Prefecture, 960-1295, Japan.
Ryuichi TogawaDepartment of Pulmonary Medicine, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima City, Fukushima Prefecture, 960-1295, Japan.
Yuki SatoDepartment of Pulmonary Medicine, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima City, Fukushima Prefecture, 960-1295, Japan.
Xintao WangDepartment of Pulmonary Medicine, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima City, Fukushima Prefecture, 960-1295, Japan.
Takefumi NikaidoDepartment of Pulmonary Medicine, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima City, Fukushima Prefecture, 960-1295, Japan.
Naoko FukuharaDepartment of Pulmonary Medicine, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima City, Fukushima Prefecture, 960-1295, Japan.
Kenya KanazawaDepartment of Pulmonary Medicine, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima City, Fukushima Prefecture, 960-1295, Japan.
Yoshinori TaninoDepartment of Pulmonary Medicine, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima City, Fukushima Prefecture, 960-1295, Japan.
Yoko ShibataDepartment of Pulmonary Medicine, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima City, Fukushima Prefecture, 960-1295, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCough-specific visual analogue scale (VAS) is widely used to assess cough severity and frequency; however, clinically meaningful thresholds for treatment response in chronic cough (CC) remain uncertain in routine practice.

objectivesTo determine minimum clinically important differences (MCIDs) for cough VAS severity and frequency using real-world data anchored to both objective cough frequency and patient-reported quality of life.

methodsIn this prospective observational study, 103 patients with CC were evaluated before and after standard treatment. Cough severity and frequency were assessed using 100-mm VAS, health-related quality of life using the Leicester Cough Questionnaire (LCQ), and 24-hour cough frequency (CoFr

resultsVAS severity and frequency showed moderate, statistically significant correlations with both LCQ and CoFr

conclusionsIn the present study, both ΔVAS of 24 mm and %ΔVAS of 60-65% reduction in cough VAS represented clinically meaningful improvement. Percentage-based MCIDs may complement absolute thresholds across a range of baseline severity, supporting the use of VAS in clinical practice and trials.

Indexed as

Chronic CoughCoughMinimal Clinically Important DifferenceVisual Analog ScaleAdultAgedFemaleHumansMaleMiddle AgedPatient Reported Outcome MeasuresProspective StudiesQuality of LifeROC CurveSeverity of Illness IndexSurveys and QuestionnairesChronic coughClinically minimum important differenceLeicester cough monitorLeicester cough questionnaireReal-world studyVisual analogue scale

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.